
Opinion|Videos|December 3, 2024
The Impact of Biomarkers and Modern Disease-Modifying Therapies in MS
Author(s)Gabriel Pardo, MD, FAAN, Martin Belkin, DO
Panelists discuss how modern multiple sclerosis (MS) management has evolved from symptomatic treatment to a proactive, personalized approach leveraging advanced biomarkers and sophisticated disease-modifying therapies. The focus has shifted toward early intervention, precise monitoring, and comprehensive disease control, significantly improving patient outcomes and quality of life.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please share how your management of MS has changed in recent years with the availability of biomarkers and highly efficacious disease-modifying therapies.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Anti-IL6R Therapy Effective in Reducing NMOSD and MOGAD Disease Activity
2
Taysha Doses First Patient in Pivotal Trial for Rett Syndrome Gene Therapy TSHA-102, Aligns With FDA on BLA Plans
3
VMAT2 Inhibitor NBI-1065890 Heads to Phase 2 Study in Tardive Dyskinesia
4
Phase 3 EMBARK Data Released, CTE Associated with Dementia Risk, Pilavapadin Heads to Phase 3 Pain Studies
5












